Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Restrictions On Rx Acetaminophen Show How Practical Concerns Influence Safety Actions

This article was originally published in The Pink Sheet Daily

Executive Summary

Because the agency can move faster on Rx products than OTCs, non-prescription products will have higher acetaminophen levels than Rx drugs, at least for the time being.

You may also be interested in...



FDA’s Rx Acetaminophen Safety Program Ramps Up Enforcement

Some manufacturers have not met a deadline FDA set three years ago to limit the amount of acetaminophen in prescription combination products to no more than 325 mg.

Actavis’ MoxDuo: Can A Generic Firm Drive Growth With A Low-Dose Product?

Actavis aims to replace its Kadian pain franchise through a deal with QRxPharma for a fixed-dose combination of morphine and oxycodone.

Pressure Builds For Revamped Acetaminophen Warnings In Rx Dispensing Materials

A white paper by the National Council for Prescription Drug Programs calls on industry to harmonize Rx labeling with existing labeling for OTC medicines.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel